



modern  
pharmacology—toxicology  
volume 14

# **developments in opiate research**

edited by  
**ALBERT HERZ**



# Developments in Opiate Research

edited by ALBERT HERZ

*Department of Neuropharmacology  
Max-Planck-Institut für Psychiatrie  
Munich, Federal Republic of Germany*



Y075149



MARCEL DEKKER, INC. New York and Basel

LIBRARY OF CONGRESS CATALOGING IN PUBLICATION DATA

Main entry under title:

Developments in opiate research.

(Modern pharmacology-toxicology ; v. 14)

Includes bibliographies and index.

1. Narcotics--Physiological effect. 2. Neuro-pharmacology. 3. Pharmacology, Experimental. I. Herz, Albert (Date)

RM328.D48

615'.782

78-9745

ISBN 0-8427-6762-4

COPYRIGHT © 1978 by MARCEL DEKKER, INC.  
ALL RIGHTS RESERVED.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC.  
270 Madison Avenue, New York, New York 10016

Current printing (last digit):  
10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

ASSOCIATE EDITOR

Robert F. Johnson

University of Miami

School of Medicine

Shannon, Florida

CONVINCING EDITOR

William F. Johnson

University of Michigan

School of Medicine

Ann Arbor, Michigan

# Developments in Opiate Research

Volume 1: A Guide to Molecular Pharmacology: Opioids, Part I and II

Edited by R. H. Johnson

Volume 2: Psychopharmacological Treatments of Opioid Dependence

Edited by Robert F. Johnson

Volume 3: The Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 4: Opioid Receptors: Location and Molecular Biology

Edited by Robert F. Johnson

Volume 5: Methods in Molecular Pharmacology

Edited by Robert F. Johnson

Volume 6: The Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 7: Opioid Antagonists: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 8: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 9: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 10: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 11: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 12: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 13: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 14: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 15: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 16: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 17: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

Volume 18: Opioid System: Pharmacology and Therapeutics

Edited by Robert F. Johnson

# MODERN PHARMACOLOGY-TOXICOLOGY

*A Series of Monographs and Textbooks*

## COORDINATING EDITOR

*William F. Bousquet*

Division of Biological Research  
Searle Laboratories, G. D. Searle & Co.  
Chicago, Illinois

## ASSOCIATE EDITOR

*Roger F. Palmer*

University of Miami  
School of Medicine  
Miami, Florida

- Volume 1**    A Guide to Molecular Pharmacology-Toxicology, Parts I and II  
*Edited by R. M. Featherstone*
- Volume 2**    Psychopharmacological Treatment: Theory and Practice  
*Edited by Herman C. B. Denber*
- Volume 3**    Pre- and Postsynaptic Receptors  
*Edited by Earl Usdin and William E. Bunney, Jr.*
- Volume 4**    Synaptic Receptors: Isolation and Molecular Biology  
*Eduardo De Robertis*
- Volume 5**    Methods in Narcotics Research  
*Edited by Seymour Ehrenpreis and Amos Neidle*
- Volume 6**    Horizons in Clinical Pharmacology  
*Edited by Roger F. Palmer*
- Volume 7**    Synthetic Antidiarrheal Drugs: Synthesis—Preclinical and Clinical Pharmacology  
*Edited by Willem Van Bever and Harbans Lal*
- Volume 8**    Receptors and Mechanism of Action of Steroid Hormones, Parts I and II  
*Edited by Jorge R. Pasqualini*
- Volume 9**    Hormone-Receptor Interaction: Molecular Aspects  
*Edited by Gerald S. Levey*
- Volume 10**   Structure and Function of Monoamine Enzymes  
*Edited by Earl Usdin, Norman Weiner, and Moussa B. H. Youdim*
- Volume 11**   Receptors in Pharmacology  
*Edited by John R. Smythies and Ronald J. Bradley*
- Volume 12**   Noncatecholic Phenylethylamines (in two parts)  
*Edited by Aron D. Mosnaim and Marion E. Wolf*
- Volume 13**   Biochemistry of Mental Disorders: New Vistas  
*Edited by Earl Usdin and Arnold J. Mandell*
- Volume 14**   Developments in Opiate Research  
*Edited by Albert Herz*

*Additional Volumes in Preparation*

## PREFACE

After so many centuries, it might seem pretentious to laud the recent developments in opiate pharmacology. They have, however, been quite astounding and are, for the most part, directly attributable to the initial demonstration of opiate receptors in vertebrate nervous tissue. Although this happened only five years ago, it has allowed many new insights to be gained into both the location and cellular basis of opiate actions. Perhaps most exciting of all has been the discovery of endogenous ligands for these opiate receptors, substances which comprise a whole new class of putative neurohumoral substances. Opiate research is, therefore, emerging as a central field in neurobiology and will, no doubt, continue to fascinate investigators in a wide variety of disciplines for many years to come.

What, then, has this book to offer, coming as it does at a time of such rapid expansion in knowledge? At the outset, I should emphasize that an extensive coverage of the existing literature is not provided. Instead, attention has been focused on a few selected topics, in which the most significant recent progress has been made. Nevertheless, the fact that the authors work in close proximity and collaboration has, I hope, enabled us to produce a consistent appraisal of the most exciting areas of opiate research, at least as they stood until the middle of 1977.

Production of this book owes much to the dedicated secretarial assistance of Miss M. McGeeney, Mrs. L. Müller, Frau H. Roth and Frau I. v. Unruh. Thanks are also due to Frau U. Gramsch for preparing the diagrams, to Drs. J.P. Fry, H. Osborne, M. Reddington, J. Traber and I.F. Tulloch for their help in the preparation of the text and last, but by no means least, to Marcel Dekker, Inc., for the initial impetus to start writing.

Research reported from this laboratory was supported by the Deutsche Forschungsgemeinschaft and by the Bundesministerium für Jugend, Familie und Gesundheit.

Albert Herz

## CONTRIBUTORS

JULIA BLÄSIG

JONATHAN P. FRY

ALBERT HERZ

VOLKER HÖLLT

RÜDIGER SCHULZ

HANSJÖRG TESCHEMACHER

MICHAEL WÜSTER

WALTER ZIEGLGÄNSBERGER

Department of Neuropharmacology  
Max-Planck-Institut für Psychiatrie  
Munich, Federal Republic of Germany

BERND HAMPRECHT

Max-Planck-Institut für Biochemie  
Martinsried, Federal Republic of Germany

## CONTENTS

Preface	iii
Contributors	ix

### Chapter 1    THE OPIATE RECEPTORS 1

Volker Höllt and Michael Wüster

Introduction. . . . .	2
General Methodology . . . . .	4
Properties of Opiate Receptor Binding . . . . .	11
Opiate Receptor Binding Correlated with Pharmacological Activity. . . . .	24
Heterogeneity of Opiate Receptors . . . . .	32
The Influence of Tolerance/Dependence on Opiate Receptor Binding. . . . .	38
Attempts to Identify the Molecular Structure of the Receptor . . . . .	41
Concluding Remarks. . . . .	46
References. . . . .	47

### Chapter 2    ENDOGENOUS LIGANDS OF OPIATE RECEPTORS 67                   (ENDORPHINS)

Hansjörg Teschemacher

Introduction. . . . .	68
Detection of the Endogenous Ligands of Opiate Receptors . . . . .	69
Structural Characteristics of the Endorphins . . . . .	75



Opioid Properties of the Endorphins . . . . .	88
The Endogenous Character of the Endorphins. . . . .	104
Summary . . . . .	124
References . . . . .	125

### Chapter 3    SITES OF OPIATE ACTION IN THE CENTRAL NERVOUS SYSTEM 153

Albert Herz

Introduction. . . . .	154
Acute Opiate Action . . . . .	154
Chronic Opiate Action . . . . .	165
Sites of Opiate Action Discussed in Terms of the Regional Distribution of Opiate Receptors . . . . .	175
Summary . . . . .	178
References. . . . .	180

### Chapter 4    ACTIONS OF OPIOIDS ON SINGLE NEURONS 193

Walter Zieglgänsberger and Jonathan P. Fry

Introduction. . . . .	194
Some Methodological Considerations: Microelectrophoresis and Recording Technique . . . . .	196
Extracellular Studies in Vertebrates. . . . .	197
Intracellular Recordings. . . . .	211
Actions of Endogenous Opiate Receptor Ligands. . . . .	215
Neurons in the Guinea Pig Myenteric Plexus and Mouse Vas Deferens . . . . .	218
Studies in Morphine Tolerant/Dependent Animals . . . . .	221
Invertebrates . . . . .	223

Concluding Remarks. . . . .	224
References. . . . .	226

Chapter 5	THE USE OF ISOLATED ORGANS TO STUDY THE MECHANISM OF ACTION OF NARCOTIC ANALGESICS	241
-----------	--	-----

Rüdiger Schulz

Introduction. . . . .	242
Isolated Organs Used in Opiate Research . . . . .	242
The Isolated Guinea Pig Ileum to Study the Action of Opiates . . . . .	245
Conclusions . . . . .	265
References. . . . .	266

Chapter 6	ON THE ROLE OF BRAIN CATECHOLAMINES IN ACUTE AND CHRONIC OPIATE ACTION	279
-----------	---	-----

Julia Bläsing

Introduction. . . . .	280
Acute Opiate Action . . . . .	281
Chronic Opiate Action . . . . .	307
Summary and General Conclusions . . . . .	329
References. . . . .	331

Chapter 7	OPIOIDS AND CYCLIC NUCLEOTIDES	357
-----------	--------------------------------	-----

Bernd Hamprecht

Introduction. . . . .	358
Cyclic Nucleotides and Acute Actions of Opioids. . . . .	360

Cyclic Nucleotides and Chronic Actions of Opioids. . . . .	374
Calcium Ions and Opiate Action. . . . .	383
Conclusion. . . . .	386
References. . . . .	389

Chapter 8     OPIATE TOLERANCE AND DEPENDENCE: SOME CONCLUDING REMARKS	407
---	-----

Albert Herz and Julia Bläsing

References. . . . .	411
Subject Index . . . . .	415

## Chapter 1

### THE OPIATE RECEPTORS

---

VOLKER HÖLLT and MICHAEL WÜSTER

Max-Planck-Institut für Psychiatrie  
Munich, Federal Republic of Germany

1.0	Introduction	2
2.0	General methodology	4
2.1	Principle of measuring high affinity binding	4
2.2	Specificity of binding	6
2.3	Parameters of opiate receptor binding	9
3.0	Properties of opiate receptor binding	11
3.1	Binding characteristics	11
3.1.1	Influences of ions	11
3.1.2	Influence of pH	14
3.1.3	Influence of temperature	15
3.1.4	Influence of preincubation	16
3.1.5	Influence of enzymes and protein-modifying reagents	17
3.2	Localization of opiate receptors	18
3.2.1	Regional distribution of opiate receptors	18
3.2.2	Subcellular localization of opiate receptors	19
3.2.3	Opiate receptors in cultured cells	20
3.3	Development of opiate receptors	21
3.3.1	Phylogenetic development	21
3.3.2	Ontogenetic development	22
3.4	Environmental factors	23
4.0	Opiate receptor binding correlated with pharmacological activity	24
4.1	Isolated preparations	24
4.2	Intact animals	26

4.3	Direct comparison between receptor occupation <u>in vivo</u> and pharmacological effect in intact animals	29
5.0	Heterogeneity of opiate receptors	32
5.1.	Indication for multiple receptors from the pharmacological activity	32
5.2	Indication for multiple receptors from binding studies <u>in vitro</u>	33
5.3	Indication for cooperative binding	35
5.4	"Apparent" heterogeneity of opiate binding	37
6.0	The influence of tolerance/dependence on opiate receptor binding	38
7.0	Attempts to identify the molecular structure of the receptor	41
7.1	Structure - activity relationships	41
7.2	Membrane constituents as putative recognition sites	42
7.3	Receptor isolation from nervous tissue	44
8.0	Concluding remarks	46
	References	47

## 1.0 INTRODUCTION

It has long been assumed that opiates exert their pharmacological action via the occupation of receptors in central and peripheral nervous tissue. Indirect evidence in support of this hypothesis has been obtained from research into the specificity of pharmacological action of opiates. For example, opiates have been found to induce characteristic effects, such as analgesia, changes in mood, respiratory depression and constipation. Such effects are evoked by some narcotics, e.g. etorphine or sufentanyl, after the administration of extremely low doses (in the range of 1 nmole/kg) which suggests interaction with a minute population of recognition sites. Specific recognition sites for narcotics are also implicated by the finding that "opiate activity" is elicited by molecules with common structural features,

which, in turn, would argue for the necessity for a specific complementary receptor.

Despite these observations, initial experiments aimed at directly demonstrating opiate receptors, either by studying the binding of opiates to nervous tissues in vitro (van Praag and Simon, 1966; Scrafani et al., 1969; Höllt and Teschemacher, 1972; Seeman et al., 1972) or by examining the brain distribution of opiates after injection into animals in vivo (Mulé and Woods, 1962; Ingoglia and Dole, 1970; Clouet and Williams, 1973) were unsuccessful. The main drawback of these studies was the inability to demonstrate a high affinity binding component in brain tissue, which is taken as a necessary criterion of receptor binding (see section 2.1). A major reason for this failing was that the degree of non-specific binding observed in the earlier experiments tended to overshadow the small fraction of specific interactions with receptor sites. Although this problem was not totally overcome by Goldstein et al. (1971), these workers were able to demonstrate a specific opiate binding component in mouse brain, which accounted for only 2% of the total binding.

The breakthrough in identification of opiate receptor binding came in 1973. The availability of tritiated opiates of high specific radioactivity enabled the use of extremely low concentrations of opiates in the binding determination. With these highly labelled compounds, three groups independently (Pert and Snyder, 1973a; Simon et al., 1973; Terenius, 1973a) demonstrated a high affinity binding of opiates to rat brain tissue, which appeared to reflect the interaction of the compounds with pharmacologically relevant receptor sites. As a result of these findings, there has been a rapid proliferation of data in this field as reflected by the numerous reviews on the subject of opiate receptor research (Goldstein, 1974; Snyder, 1975a,b; Simon, 1975a,b,c; Pert, 1976; Snyder, 1977; Snyder and Simantov, 1977). It is the aim of this review to discuss several aspects of these results and to emphasise some areas not previously reviewed in detail.

It should be noted that the term "receptor", as traditionally conceived in pharmacology, describes a putative macromolecular entity, which possesses both the ability to bind a ligand and the capacity to initiate a pharmacological response. It has become common practice to use the term "receptor(s)" when referring to binding sites of high affinity and specificity, and

has been generally adhered to in this review except where specifically indicated.

## 2.0 GENERAL METHODOLOGY

### 2.1 Principle of measuring high affinity binding

In practice, the binding of ligands is measured to relatively crude tissue preparation rather than to purified receptors. Therefore, the binding of a ligand in such a system has to be considered to consist of several components. In the simplest case, besides the binding to the receptor sites which is of a high affinity and saturable, another binding component exists, which is non-saturable and has commonly been termed non-specific. Hydrophobic interactions between the ligands and a wide variety of lipidic tissue components are responsible for the latter type of binding. This had been shown for the non-specific binding of several opiates (Höllt and Teschemacher, 1975).

Figure 1 shows the result of an experiment, in which the interactions of an opiate with specific and non-specific binding sites were investigated. Increasing concentrations of the opiate agonist etorphine (tritium labelled to high specific activity) was incubated together with rat brain homogenate. The upper curve shows the results obtained for the binding of  $^3\text{H}$ -etorphine, whilst the lower curve represents the binding of  $^3\text{H}$ -etorphine together with a large excess of non-labelled etorphine - high enough to displace the labelled compound from the saturable sites. This latter type of etorphine binding is characteristic of non-specific, non-saturable binding. The difference curve obtained by subtracting the values of non-specific binding from those of total binding is hyperbolic indicating the increasing saturation of a finite population of binding sites. This figure also illustrates the importance of using low concentration of ligands in performing the binding assay, since it can be seen that the ratio of high affinity to non-specific binding is highest at very low concentrations of etorphine. In general, for such experiments radiolabelled opiates with a high affinity for receptors should be preferred to compounds of lower affinity, since receptor occupation can be achieved at concentrations at which non-specific binding is minimal.

Further improvements in optimising the high affinity/non-specific binding ratio has been made by a filtration method, which separates bound from free ligand while the non-specific binding is lowered by several washings (Pert and Snyder, 1973a). In order to prevent washing out of the specifically bound drug, washing is carried out rapidly (only for seconds) and at low temperature. These steps ensure that ligand dissociation from specific sites (half-life in the range of minutes; Pert and Snyder, 1973b) is kept to a minimum.

Although this technique has been successfully used with most radiolabelled opiates, there are occasions




Fig. 1. Saturation curve obtained by binding of increasing amounts of  $^3\text{H}$ -etorphine to crude rat brain membranes diluted 1 : 100 with 50 mM sodium phosphate buffer (pH 7.4 at 25°C). Total binding is graphed by  $\circ\text{---}\circ$ . The unspecific binding is represented by the lower curve, measured as the binding in the presence of 1  $\mu\text{M}$  unlabelled etorphine ( $\circ\text{---}\circ$ ). The difference curve represents the calculated amount of specifically bound etorphine ( $\text{x}\text{---}\text{x}$ ).



where difficulties can be encountered. For instance, the non-specific binding of  $^3\text{H}$ -loperamide - an antidiarrheal agent with a high affinity for opiate receptor sites - is not significantly reduced by the filter washing procedure (Wüster, unpublished). Since the non-specific binding of this compound is very high (presumably due to its high surface activity), it is almost impossible to measure specific opiate binding with  $^3\text{H}$ -loperamide.

Difficulties in separating specific binding from non-specific binding have also been reported by Cox et al. (1976) who attempted to label opiate receptors by radioactive photoaffinity derivatives of levorphanol. Photoaffinity labelling is a technique by which reversible ligand binding can be made irreversible, following irradiation by ultraviolet light. The amount of reversible binding to specific sites in mouse brain homogenate using N- $\beta$  (p-azidophenyl)[ $\alpha$ - $^3\text{H}$ ]-ethylnor-levorphanol ( $^3\text{H}$ -APL) was similar to that obtained with  $^3\text{H}$ -etorphine. However, non-specific binding was seven- to eightfold higher for  $^3\text{H}$ -APL than for  $^3\text{H}$ -etorphine. This high non-specific binding of  $^3\text{H}$ -APL might at least partly explain why no significant covalent attachment of  $^3\text{H}$ -APL to receptor sites could be detected. However, this technique will be of great use in the isolation of opiate receptors (see section 7.3), if conditions are found under which a more preferential labelling of the receptor can be achieved.

Another experimental manipulation for increasing the specific to non-specific binding ratio is the use of selected areas of nervous tissue or subcellular fractions which are rich in receptor content (see section 3.2.2.).

## 2.2 Specificity of binding

It has been pointed out (Dole et al., 1975; Goldstein et al., 1974) that the establishment of a saturable high affinity opiate binding component is insufficient proof of binding to the pharmacologically relevant receptors, since "silent" receptors (Goldstein et al., 1974) or "acceptors" (Birnbaumer et al., 1974) might also bind opiates with a high affinity without initiating a pharmacological response.

In order to ensure that the high affinity binding of ligands represents binding to opiate receptor sites, it has to be shown that pharmacological activity of the drugs results from their binding. The specificity of